The identification of risk of spontaneous fetal loss through second-trimester maternal serum screening
- PMID: 16098861
- DOI: 10.1016/j.ajog.2004.12.017
The identification of risk of spontaneous fetal loss through second-trimester maternal serum screening
Abstract
Objective: The purpose of this study was to investigate associations between risk of spontaneous fetal loss and risk estimates for Down syndrome, trisomy 18, and neural tube defects assigned by second-trimester maternal serum screening.
Study design: The study involved 264,653 women with available pregnancy outcomes who were screened between 15 and 20 weeks of gestation in the Ontario Maternal Serum Screening Program between October 1995 and September 2000. Pregnancies complicated by fetal chromosomal or structural abnormalities, insulin-dependent diabetes mellitus, and multiple pregnancies were excluded. Spontaneous fetal loss was defined as spontaneous miscarriage and intrauterine fetal demise as classified by the ICD-9 system, but including only those > or = 15 weeks of gestation. Women were grouped according to risk estimates for Down syndrome, trisomy 18, and neural tube defects, respectively. Spontaneous fetal loss rates by each risk group were evaluated after adjusting for losses associated with maternal age and amniocentesis.
Results: Fetal loss rates increased in women with risk estimates of > or = 1 in 1110 for trisomy 18 or neural tube defects, and > or = 1 in 130 for Down syndrome. The excessive fetal loss rates for these 3 groups of women were 14.4%, 3.2%, and 1.5% respectively.
Conclusion: Fetal loss rate markedly increased in women with high-risk estimates for trisomy 18, neural tube defects, and Down syndrome. Risk estimates assigned by triple marker screening may provide an early means of stratifying pregnancies into risk for fetal loss.
Similar articles
-
Triploidy identified through second-trimester serum screening.Prenat Diagn. 2005 Mar;25(3):229-33. doi: 10.1002/pd.1115. Prenat Diagn. 2005. PMID: 15791661
-
Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.J Matern Fetal Med. 1996 Mar-Apr;5(2):70-3. doi: 10.1002/(SICI)1520-6661(199603/04)5:2<70::AID-MFM4>3.0.CO;2-N. J Matern Fetal Med. 1996. PMID: 8796771
-
Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results.Prenat Diagn. 2001 Jan;21(1):46-51. Prenat Diagn. 2001. PMID: 11180240
-
Maternal serum screening for neural tube defects and fetal chromosome abnormalities.West J Med. 1993 Sep;159(3):312-7. West J Med. 1993. PMID: 7694429 Free PMC article. Review.
-
Down syndrome: prenatal risk assessment and diagnosis.Am Fam Physician. 2000 Aug 15;62(4):825-32, 837-8. Am Fam Physician. 2000. PMID: 10969860 Review.
Cited by
-
Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions: A Health Technology Assessment.Ont Health Technol Assess Ser. 2019 Feb 19;19(4):1-166. eCollection 2019. Ont Health Technol Assess Ser. 2019. PMID: 30847010 Free PMC article.
-
Prenatal Biochemical Screening and a Woman's Long-Term Risk of Cancer: A Population-Based Cohort Study.JNCI Cancer Spectr. 2019 Oct 4;4(1):pkz077. doi: 10.1093/jncics/pkz077. eCollection 2020 Feb. JNCI Cancer Spectr. 2019. PMID: 32110774 Free PMC article.
-
Recurrent Pregnancy Loss Etiology, Risk Factors, Diagnosis, and Management. Fresh Look into a Full Box.J Clin Med. 2023 Jun 15;12(12):4074. doi: 10.3390/jcm12124074. J Clin Med. 2023. PMID: 37373766 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical